Safety and Effectiveness of Oral Atogepant for Preventing Chronic or Episodic Migraine in Korean Adults

What this Trial Is About

This research focuses on adults in Korea who have chronic or episodic migraine, a neurological condition causing moderate to severe headaches often accompanied by nausea, vomiting, and sensitivity to light and sound. The study aims to evaluate the safety and effectiveness of atogepant, a medication approved for preventing migraines, when used in regular clinical settings. Participants will take atogepant oral tablets as prescribed by their doctors, following the approved local guidelines. The study involves approximately 3000 adults who will be observed during their routine medical care while using this medication. There are no additional treatments or burdens beyond what their physicians recommend. During the study, participants will attend their usual clinic or hospital visits up to 12 weeks. Researchers will monitor and record any adverse events, including serious or unexpected reactions, as well as common side effects. The main outcomes focus on safety measures related to atogepant use. The study will continue until May 2029, ensuring thorough observation of participants under typical care conditions.

Post-Marketing Study to Assess the Safety and Effectiveness of Oral Atogepant in Korean Adult Participants for the Prevention of Chronic or Episodic Migraine